8-K - Sigyn Therapeutics, Inc. | StockGist

Current Report Details

Event Type

Material Agreement+3 More

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

Entry into a Material Definitive Agreement On August 8, 2025, Sigyn Therapeutics, Inc. (the “Company”) entered into a Convertible Note Purchase Agreement (the “

Material Agreement

$550.0K$500.0K$110.0K$100.0K

3.02

Unregistered Sale of Securities . See Item 1.01. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; C

Securities Issuance

8.01

Other Events. The Company’s directors’ and officers’ liability insurance policy expired on August 4, 2025. The Company did not extend the policy and has not yet

Other Event

9.01

FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits Exhibit No. Title 99.1 Convertible Note Purchase Agreement 104 Cover Page Interactive Data File (formatted as In

Exhibits Only

Source Document

Exhibits (2)

8-K

99.1

EX-99.1